JYSELECA is a JAK1-preferential inhibitor with more than five-fold higher potency for JAK1 over other JAK isoforms, as measured in biochemical assays, the clinical relevance of which is uncertain1,2
Proinflammatory cytokine signalling via JAK1-containing protein complexes has been implicated in UC pathogenesis3,4
In human cellular assays, JYSELECA preferentially inhibited JAK1/JAK3-, JAK1/JAK2- and JAK1/TYK2-mediated signalling, with functional selectivity over cytokine receptors that signal via pairs of JAK2 or JAK2/TYK25
The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known
MoA, mode of action; JAK, Janus kinase; TYK, tyrosine kinase; UC, ulcerative colitis.
References: 1. Danese S, Argollo M, Le Berre C, et al. Gut 2019;68:1893–1899. 2. Salas A, Hernandez-Rocha C, Duijvestein M, et al. Nat Rev Gastroenterol Hepatol 2020;17:323–337. 3. Schwartz DM, Kanno Y, Villarino A, et al. Nat Rev Drug Discov 2017;17:78. 4. Virtanen AT, Haikarainen T, Raivola J, et al. BioDrugs 2019;33:15–32. 5. Galien R, Vayssiere B, de Vos S, et al. Arthritis Rheum 2013;65 Suppl 10:Abstract 478.
GB-UC-JY-202303-00004 | Date of preparation: October 2023
Adverse events should be reported.
For Great Britain, reporting forms and information can be found at yellowcard.mhra.gov.uk or via the Yellow Card app (download from the Apple App Store or Google Play Store). Adverse events should also be reported to Galapagos via email to DrugSafety.UK.Ireland@glpg.com or 0800 072 7878.
Adverse events should be reported.
For Northern Ireland, reporting forms and information can be found at yellowcard.mhra.gov.uk or via the Yellow Card app (download from the Apple App Store or Google Play Store). Adverse events should also be reported to Galapagos via email to DrugSafety.UK.Ireland@glpg.com or 0800 072 7878.
Adverse events should be reported.
For the Republic of Ireland, reporting forms and information can be found at www.hpra.ie and can be reported to HPRA on +353 1 6764971.
Adverse events should also be reported to Galapagos via email to DrugSafety.UK.Ireland@glpg.com or 00800 7878 1345.
Jyseleca, Galapagos and the Galapagos logo are registered trademarks of Galapagos NV.
GB-IBD-FIL-202211-00008
Date of preparation: November 2023
Contact Us
Galapagos Biotech Ltd
148 Belmont Rd, Uxbridge UB8 1QS
medicalinfo@glpg.com
Jyseleca, Galapagos and the Galapagos logo are registered trademarks of Galapagos NV.
GB-IBD-FIL-202211-00008
Date of preparation: November 2023
Contact Us
Galapagos Biotech Ltd
148 Belmont Rd, Uxbridge UB8 1QS
medicalinfo@glpg.com
© 2023 Galapagos NV. All rights reserved.
This link will take you away from the Galapagos website and you will be re-directed to a non-Galapagos website. Galapagos does not accept liability for sites controlled by third-parties.